RCUS Stock Summary and Trading Ideas (Arcus Biosciences | NYSE:RCUS)

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Arcus Biosciences trades on the NYSE stock market under the symbol RCUS.

As of October 1, 2026, RCUS stock price declined to $25.36 with 77,322 million shares trading.

RCUS has a beta of 0.73, meaning it tends to be less sensitive to market movements. RCUS has a correlation of 0.03 to the broad based SPY ETF.

RCUS has a market cap of $3.19 billion. This is considered a Mid Cap stock.

Last quarter Arcus Biosciences reported $41 million in Revenue and -$.72 earnings per share. This beat revenue expectation by $19 million and exceeded earnings estimates by $.13.

In the last 3 years, RCUS traded as high as $31.74 and as low as $6.50.

The top ETF exchange traded funds that RCUS belongs to (by Net Assets): IJR, VTI, IWM, XBI, VB.

RCUS has outperformed the market in the last year with a price return of +86.5% while the SPY ETF gained +15.2%. However, in the short term, RCUS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -17.7% vs +2.0% return in SPY. But in the last 2 weeks, RCUS shares have fared better than the market returning +2.9% compared to SPY +1.0%.

RCUS support price is $24.94 and resistance is $26.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RCUS shares will trade within this expected range on the day.